Author

Mehregan Nematian‐Samani

Observed names: M Nematian-Samani, M. Nematian-Samani, Mehregan Nematian-Samani, Nematian-Samani, Mehregan

Institutions: Johnson & Johnson (United States), Johnson & Johnson (Germany)

Observed institutions: Johnson & Johnson (United States), University of Cologne, Kliniken Maria Hilf, Johnson & Johnson (Germany), Janssen (Germany), University Hospital Cologne

OpenAlex ID: A5057745878

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

2025 · Byoung Chul Cho, Weimin Li, et al. · Journal of Thoracic Oncology · 38

Targeted Investigational Treatment Analysis of Novel Anti‐androgen (TITAN) study: ultralow prostate‐specific antigen decline with apalutamide plus androgen‐deprivation therapy

2024 · Axel S. Merseburger, Neeraj Agarwal, et al. · British Journal of Urology · 28

A meta-analysis of the efficacy of quinolone containing otics in comparison to antibiotic–steroid combination drugs in the local treatment of otitis externa

2011 · R. Mösges, M. Nematian-Samani, et al. · Current Medical Research and Opinion · 19

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

2023 · Christos Chouaid, Lise Bosquet, et al. · Advances in Therapy · 18

Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)

2024 · Benjamin L. Maughan, Yanfang Liu, et al. · Prostate Cancer and Prostatic Diseases · 15

The impact of androgen receptor pathway inhibitors as starting treatment in metastatic castration-sensitive prostate cancer on patient outcomes (OASIS Japan)

2025 · Masaki Shiota, Yanfang Liu, et al. · Scientific Reports · 10

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS).

2024 · Benjamin L. Maughan, Suneel Mundle, et al. · Journal of Clinical Oncology · 4

P3.12.46 Enhanced vs Standard Dermatologic Management With Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT

2025 · B.C. Cho, W. Li, et al. · Journal of Thoracic Oncology · 1

Ist Ihr Patient zu lang verschnupft?

2014 · Mehregan Nematian-Samani, Ralph Mösges · MMW - Fortschritte der Medizin · 1

Pcr95 Measuring Patient-reported Dermatologic Side Effects of Cancer Treatment: Psychometric Evaluation of the Skindex-16 in Non-small Cell Lung Cancer

2026 · Julia Schuchard, Stefan Englert, et al. · Value in Health

PP01.142: First Results from the COCOON Treatment Substudy in Managing Moderate to Severe Dermatologic Adverse Events in Participants with EGFR-mutated Advanced NSCLC Treated with First-line Amivantamab-Lazertinib

2026 · Alexander I. Spira, Maxwell B. Sauder, et al. · Journal of Thoracic Oncology

260MO Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC)

2023 · M. Shiota, S.D. Mundle, et al. · Annals of Oncology

CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

2022 · C Chouaid, N Girard, et al. · Value in Health

Haut und Schleimhäute

2011 · F. C. Weber, P. Esser, et al. · Allergo Journal

Works count: 15

Citation count: 134

H-index: 6

I10-index: 6